Published in J Natl Cancer Inst on February 21, 2001
Bevacizumab in Extensive Small Cell Lung Cancer (CPC) | NCT00930891
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer (2008) 0.91
Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res (2011) 0.89
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer (2015) 0.88
Lung cancer 7: management of lung cancer in elderly patients. Thorax (2003) 0.84
Topotecan in the treatment of relapsed small cell lung cancer. Onco Targets Ther (2008) 0.81
Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer (2006) 0.81
Small-cell lung cancer: 8 years experience of a single multidisciplinary team. J Oncol (2008) 0.79
Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model. Ther Clin Risk Manag (2006) 0.78
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol Oncol (2015) 0.78
Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. J Thorac Oncol (2010) 0.76
Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Br J Cancer (2008) 0.75
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study. Br J Cancer (2006) 0.75
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients. Br J Cancer (2017) 0.75
Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer. J Natl Cancer Inst (2001) 0.75
Modified one-day etoposide and cisplatin combination for previously untreated extensive-disease small-cell lung cancer: A retrospective evaluation of 36 cases. Mol Clin Oncol (2015) 0.75
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet (1993) 6.08
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst (1991) 4.24
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst (1995) 3.25
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys (2000) 2.58
Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol (2000) 2.48
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol (2013) 2.42
Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer (2004) 2.22
Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest (1995) 2.22
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol (2006) 2.18
Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol (1992) 2.08
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res (1993) 1.98
Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J (2003) 1.97
Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest (1995) 1.92
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys (1991) 1.91
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol (2004) 1.81
Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol (1999) 1.70
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med (1993) 1.69
Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol (1998) 1.66
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer (2001) 1.66
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer (2003) 1.63
Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol (1998) 1.60
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol (1989) 1.60
The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol (1997) 1.59
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol (2010) 1.58
[Smoking habits, attitudes and knowledges of medical students of Medicine, Pharmacy and Odonto-Stomatology's Faculty of Dakar, Senegal]. Rev Mal Respir (2003) 1.54
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Management strategy of pulmonary nodule in 2013. Diagn Interv Imaging (2013) 1.47
Small cell carcinoma of the pleura. A case report. Lung Cancer (1996) 1.47
Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol (1995) 1.46
Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J (1997) 1.45
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol (2001) 1.44
Multiple temporal cluster detection. Biometrics (2001) 1.43
Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study. Lung Cancer (2000) 1.39
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer (1985) 1.37
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol (1995) 1.36
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer (1996) 1.32
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol (1995) 1.31
Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab Disord (2000) 1.31
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol (2001) 1.28
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer (2008) 1.27
Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer (2000) 1.23
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.23
Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst (1992) 1.22
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol (1996) 1.21
Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer (1994) 1.20
Effects of cigarette smoking on reproduction. Hum Reprod Update (2010) 1.20
Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol (1996) 1.19
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology (2011) 1.16
Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest (1998) 1.16
Silica-associated connective tissue disease. A study of 24 cases. Medicine (Baltimore) (1995) 1.16
Lung cancer in HIV infected patients: facts, questions and challenges. Thorax (2006) 1.13
Benign mediastinal lymphadenopathy in congestive heart failure. Chest (2001) 1.12
Diagnosis of smear-negative pulmonary tuberculosis using sequence capture polymerase chain reaction. Am J Respir Crit Care Med (1997) 1.12
Induction treatment before surgery for non-small cell lung cancer. Lung Cancer (2003) 1.12
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer (2009) 1.11
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer (2001) 1.10
Epidemiological study of farmer's lung in five districts of the French Doubs province. Thorax (1988) 1.10
Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer (2001) 1.10
Docetaxel and interstitial pulmonary injury. Ann Oncol (1997) 1.09
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol (2007) 1.07
Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect (2004) 1.06
Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst (1996) 1.06
Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer (2005) 1.06
Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Cancer Res (1998) 1.06
Assessment of the current status of iodine prophylaxis in Bosnia and Herzegovina Federation. J Pediatr Endocrinol Metab (2001) 1.06
The analysis of asthma control under a Markov assumption with use of covariates. Stat Med (2003) 1.05
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol (1986) 1.05
Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol (2002) 1.05
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol (1998) 1.04
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res (1998) 1.04
Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol (1994) 1.04
Vitamin D metabolism in tuberculosis. Production of 1,25(OH)2D3 by cells recovered by bronchoalveolar lavage and the role of this metabolite in calcium homeostasis. Am Rev Respir Dis (1988) 1.03
Prevalence of asthma and respiratory symptoms in dairy farmers in the French province of the Doubs. Am J Respir Crit Care Med (1998) 1.03
Interleukin-1 release by alveolar macrophages in asthmatic patients and healthy subjects. Int Arch Allergy Appl Immunol (1990) 1.02
Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. Ann Rheum Dis (2004) 1.02
[Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial]. Gastroenterol Clin Biol (1994) 1.02